The role of randomization in clinical studies: Myths and beliefs

Journal of Clinical Epidemiology

Volumn 52, Issue 6, 1999, Pages 487-497

  Abel, Ulrich ^a   Koch, Armin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Clinical studies; Epistemology; Observational studies; Randomization

Indexed keywords

CLINICAL TRIAL; LITERATURE; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; STATISTICAL ANALYSIS; THEORY;

EID: 0033151796     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(99)00041-4     Document Type: Note

References (87)

1. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2: 769-782.
2. Feinstein AR. Current problems and future challenges in randomized clinical trials. Circulation 1984; 70: 767-774.
3. Horwitz RI. The experimental paradigm and observational studies of cause-effect relationships in clinical medicine. J Chron Dis 1987; 40: 91-99.
4. Olkin I. Statistical and theoretical considerations in meta-analysis. J Clin Epidemiol 1995; 48: 133-146.
5. Cochrane AL. Effectiveness and efficiency. Random Reflections on Health Services. Abingdon: The Nuffield Provincial Hospital Trust; 1972.
6. Feinstein AR. An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med 1983; 99: 544-550.
7. Royall RM. Current advances in sampling theory: Implications for human observational studies. Am J Epidemiol 1976; 104: 463-474.
8. Weinstein MC. Allocation of subjects in medical experiments. N Engl J Med 1974; 291: 1278-1285.
9. Department of Clinical Epidemiology and Biostatistics MU-HSC. How to read clinical journals: V. To distinguish useful from useless or even harmful therapy. Can Med Assoc J 1981; 124: 1156-1162.
10. Cowan DH. The ethics of trials of ineffective therapy. IRB: A Review of Human Subjects Research 1981; 3: 10-11.
11. Doll R. Summation of a conference. NY Acad Sci 1994; 703: 310-313.
12. Gaus W. Kontrollierte therapiestudien bei niedergelassenen ärzten. Münch Med Wochenschr 1995; 137: 63-66.
13. Schäfer H. Methodik Kontrollierter Klinischer Therapiestudien. Heidelberg, Universität Heidelberg: Schriftenreihe des Instituts für Medizinische Biometrie und Informatik; 1993.
14. Biefang S, Köpcke W, Schreiber MA. Manual für die durchführung von therapiestudien. In: Koller S, Reichertz PL, Überla K, Eds. Medizinische Informatik und Statistik. Berlin: Springer-Verlag; 1979.
15. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. Am J Epidemiol 1974; 66: 688-701.
16. Holland PW. Statistics and causal inference. J Am Stat Assoc 1986; 81: 945-970.
17. Abel U. Chemotherapie Fortgeschrittener Karzinome. Stuttgart; Hippokrates-Verlag; 1995.
18. Byar DP. Why data bases should not replace randomized clinical trials. Biometrics 1980; 36: 337-342.
19. Dupont WD. Randomized vs. Historical clinical trials: Are the benefits worth the costs? Am J Epidemiol 1985; 122: 940-946.
20. Green SB, Byar DP. Using observational data from registries to compare treatments: The fallacy of omnimetrics. Stat Med 1984; 3: 361-370.
21. Haines SJ. Randomized clinical trials in the evaluation of surgical innovation. J Neurosurg 1979; 51: 5-11.
22. Johnson FN, Johnson S. Organisation of clinical trials: The pretrial period. In: Johnson FN, Johnson S, Eds. Clinical Trials. Oxford: Blackwell Scientific Publications, 1977: 36-82.
23. Laupacis A, Rorabeck CH, Bourne RB, Feeny D, Tugwell P, Sim DA. Randomized trials in orthopaedics: Why, how, and when? J Bone Joint Surg (American Volume) 1989; 71-A: 535-543.
24. Morgan PP. Clinical trials on trial: I. Must we always do a randomized trial? Can Med Assoc J 1981; 125: 1309-1311.
25. Pocock SJ. Clinical Trials. A Practical Approach. Chichester, PA: Wiley; 1983.
26. Rudicel S, Esdaile J. The randomized clinical trial in orthopaedics: Obligation or options? J Bone Joint Surg (American Volume) 1985; 67-A: 1284-1293.
27. Sacks H, Chalmers TC, Smith J. Randomized versus historical controls for clinical trials. Am J Med 1982; 2: 233-240.
28. Solomon MJ, Leod RS. Clinical studies in surgical journals - We have improved? Dis Colon Rectum 1993; 36: 43-48.
29. Zelen M. The role of statistics in the design and evaluation of trials in cancer medicine. In: Veronesi U, Bonadonna G, Eds. Clinical Trials in Cancer Medicine. Orlando, FL: Academic Press; 1985: 561-568.
30. Byar DP, Simon RM, Friedewald WT, Schlesselman JJ, Detets DL, Ellenberg JH, et al. Randomized clinical trials. N Engl J Med 1976; 295: 74-80.
31. Green SB. Patient heterogeneity and the need for randomized clinical trials. Control Clin Trial 1982; 3: 189-198.
32. Greenland S. Randomisation, statistics and causal inference. Epidemiology 1990; 1: 421-429.
33. Simon R. Randomized clinical trials and research strategy. Cancer Treat Rep 1982; 66: 1083-1087.
34. Armitage P. The role of randomization in clinical trials. Stat Med 1982; 1: 345-352.
35. Kempthorne O. Why randomize. J Stat Planning Inference 1977; 1: 1-25.
36. Rosenbaum PR. Observational Studies. New York. Springer; 1995.
37. Feinstein AR. An additional basic science for clinical medicine III. The challenges of comparison and measurement. Ann Intern Med 1983; 99: 705-712.
38. Hlatky MA, Lee KL, Harrell FE, Califf RT, Pryor DB, Mank DB, et al. Tying clinical research to patient care by use of an observational database. Stat Med 1984; 3: 375-384.
39. Lorenz W, Ohmann C, ImmicH H, Schreiber HL, Scheibe O, Henfarth CH, et al. Patientenzuteilung bei kontrollierten klinischen studien. Chirurg 1982; 53: 514-519.
40. SchuMacher M, Schulgen G. Planung Und Auswertung Von Klinischen Studien. Vol. 1. Freiburg, Universität Freiburg: Schriftenreihe des Instituts für Medizinische Biometrie und Medizinische Informatik; 1991.
41. Mantel N. Cautions on the use of medical databases. Stat Med 1983; 2: 355-362.
42. Cornfield J. Statistical relationships and proof in medicine. Am Stat 1954; 8: 19-23.
43. Breslow NE, Day NE. Statistical Methods in Cancer Research. Volume 1 - The Analysis of Case-Control Studies. Lyon: International Agency for Research on Cancer; 1980.
44. Susser M. Causal Thinking in the Health Sciences and Strategies of Epidemiology. New York: Oxford University Press; 1973.
45. Expert Panel. Principles for Evaluating Epidemiological Data in Regulatory Risk Assessment. Washington, DC: Federal Focus Inc.; 1996.
46. Peto R, Collins R, Gray R. Large-scale randomized evidence: Large, simple trials and overviews of trials. J Clin Epidemiol 1995; 48: 23-40.
47. Abel U, Windeler J. Comprehensive blinded prognostic rating - Eine studienform für die nichtrandomisierte bewertung von therapien. In: Hornung J, Ed. Forschungsmethoden in der Komplementärmedizin. Stuttgart: Schattauer-Verlag; 1996: 153-163.
48. Beecher HK. The powerful placebo. JAMA 1955; 159: 1602-1606.
49. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Med Sci 1976; 73: 3685-3689.
50. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. N Engl J Med 1979; 301: 687-690.
51. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Amer MM, et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985; 312: 137-141.
52. Horwitz RI, Viscoli CM, Clemens JD, Saddock RT. Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med 1990; 89: 630-638.
53. Mayes LC, Horwitz RI, Feinstein AR. A collection of 56 topics with contradictory results in case-control research. Int J Epidemiol 1988; 17: 680-685.
54. Horwitz RI, Feinstein AR. The application of therapeutic-trial principles to improve the design of epidemiologic research: A case-control study suggesting that anticoagulants reduce mortality in patients with myocardial infarction. J Chron Dis 1981; 34: 575-583.
55. Horwitz RI, Feinstein AR. Improved observational method for studying therapeutical efficacy. JAMA 1981; 246: 2455-2459.
56. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516-524.
57. Baker SG, Linderman KS. The paired availability design: A proposal for evaluating epidural analgesia during labor. Stat Med 1994; 13: 2269-2278.
58. Heuer C, Abel U. The analysis of intervention effects using an observational database. In: Abel U, Koch A, Eds. Nonrandomized Comparative Clinical Studies. Düsseldorf: Symposion Publishing; 1998.
59. Paradise JL, Bluestone CD, Bachmann RZ, Collone DK, BerNard BS, Taylor FH, et al. efficacy of tonsillectomy for recurrent throat infection in severely affected children. N Engl J Med 1984; 310: 674-683.
60. Hammermeister KE, Derouen TE, Murray J, Dodge HT. Effect of aorta coronary saphenous vein bypass graft on death: Comparison of nonrandomized medically and surgically treated cohorts with comparable coronary disease and left ventricular function. Am J Cardiol 1977; 39:925-934.
61. Cassileth BR, Lusk EJ, Guerry D, Blake AD, Walsh WP, Kascius L, et al. Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med 1991; 324: 1180-1185.
62. Chalmers TC, Celano P, Sacks HS, Smith H. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1993; 309: 1358-1361.
63. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I: Medical. Stat Med 1989; 8: 441-454.
64. Miller JN, Colditz GA, Mosteller F. How study design affects outcomes in comparisons of therapy. II: Surgical. Stat Med 1989; 8: 455-466.
65. Ottenbacher K. Impact of random assignment on study outcome: An empirical examination. Control Clin Trial 1991; 13: 50-61.
66. Ciampi A, Till JE. Null results in clinical trials: The need for a decision-theory approach. Br J Cancer 1980; 41: 618-628.
67. Pocock SJ. Randomised clinical trials [letter]. Br Med J 1977; 1: 1661.
68. Peto R. Clinical trial methodology. Biomed Special Issue 1978; 28: 24-36.
69. Feinstein AR, Sosin DM, Wells CK. The will rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312: 1604-1608.
70. Urbach P. The value of randomisation and control in clinical trials. Stat Med 1993; 12: 1421-1431.
71. Coronary Drug Project. Influence on adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980; 303: 1038-1041.
72. Fisher RA. The Design and Analysis of Experiment. Edinburgh: Oliver and Boyd; 1935.
73. Chalmers TC, Block JB, Lee S. Controlled studies in clinical cancer research. N Engl J Med 1972; 287: 75-78.
74. Cranberg L. Do retrospective controls make clinical trials "inherently fallacious"? Br Med J 1979; 2: 1265-1266.
75. Blade N. Why we need observational studies to evaluate the effectiveness of health care. Br Med J 1996; 312: 1215-1218.
76. Love JW. Drugs and operations: Some important differences. JAMA 1975; 232: 37-38.
77. Lavori PW, Louis TA, Bailar JC, Polausky M. Design for experiments - Parallel comparisons of treatment. N Engl J Med 1983; 309: 1291-1298.
78. Koch A, Windeler J, Abel U. Anwendungsbeobachtungen: Zu begriff und nutzen. Med Klin 1996; 91: 103-105.
79. Anonymous. Cross design synthesis: A new strategy for studying medical outcomes? Lancet 1992; 340: 944-946.
80. Gregory PB, Knauer CM, Kempson RL, Miller R. Steroid therapy in severe viral hepatitis. N Engl J Med 1976; 294: 681-687.
81. Miao LL. Gastric freezing: An example of the evaluation of medical therapies by randomized trials. In Bunker JP, Barnes BA, Mosteller F, Eds. Costs, Risks, and Benefits of Surgery. New York: Oxford University Press; 1977: 198-211.
82. Barsamian EM. The rise and fall of internal mammary artery ligation in the treatment of angina pectoris and the lessons learned. In: Bunker JP, Barnes BA, Mosteller F, Eds. Costs, Risks, and Benefits of Surgery. New York: Oxford University Press; 1977: 212-220.
83. Clamon GH, Feld R, Evans WK, Weiner RS, Moran EM, Blum RH, et al. Effect of adjuvant central iv hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: A randomized trial. Cancer Treatment Rep 1985; 69: 167-177.
84. Committee of Principal Investigators. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-1118.
85. The EC/IC Bypass Study Group. Failure of extracranial-intracranial bypass to reduce the risk of ischaemic stroke. N Engl J Med 1985; 313: 1191-1200.
86. Abel U, Windeler J. Erkenntnistheoretische aspekte klinischer studien. 3. Fallstudie ASI - Fehlurteile und unfundierte schlüsse in klinischen therapieprüfungen. Internistische Praxis 1997; 37: 619-629.
87. Cox DR. Summary views: A statistician's perspective. Cancer Treatm Rep 64: 533-535.